Peptidyl-histidine modification

Across TCGA cell cohorts, RNA activity of the Peptidyl-histidine modification pathway is significantly associated with the drug response of multiple features, with the BLOOD_Leukemia cohort showing a particularly strong set of associations.

The most reproducible pathway-associated features across cancer lineages are Cediranib, Tipifarnib, and KIN001-244, each associated with the pathway in up to 3 cancer types. Since the analysis shows associations rather than directional relationships, both pathway-to-partner and partner-to-pathway views are reported.

Each partner is linked to its corresponding Q-omics profile. The box plot shows the strongest association, Cediranib grouped by Peptidyl-histidine modification-low versus -high activity in BLOOD_Leukemia.

Pathway-associated features by consensus

Ranked by combined sampling and lineage consensus. X-score (pathway→partner) and Y-score (partner→pathway) are standardized regression coefficients; both directions are reported because the association is undirected. The reported p-values are derived from the association test.

Lineage	Partner feature	X-score	Y-score	p(X)	p(Y)	Sampling consensus	Lineage consensus
BLOOD_Leukemia	Cediranib →	+0.171	+0.223	.011	.033	3	3
BLOOD_Leukemia	Tipifarnib →	-0.846	-0.198	.018	.020	3	3
BLOOD_Leukemia	KIN001-244 →	-1.025	-0.292	.020	.013	3	3
BLOOD_Leukemia	PHA-793887 →	-1.247	-0.322	.011	.024	3	3
BLOOD_Myeloma	Olaparib →	+0.486	+0.456	.002	.046	3	3
LUNG_SCLC	TWS119 →	+1.284	+0.852	.020	.026	3	3

Each partner links to its Q-omics profile. Showing the 6 strongest associations by consensus.

Cediranib by Peptidyl-histidine modification activity — BLOOD_Leukemia

Explore this box plot interactively →